TRPV1 and arthritic joint disease: Injection of TRPV1 antagonists A-889425 and JNJ-17203212 systemically reduces pain behaviour and decreases peripheral A and C fibre joint afferent nerve and injury receptor firing in a model of arthritis (12, 13).In this review, we summarise the TRPV1 channel expression associated with RA reported to date, and the impact of channel alterations on the pathogenesis of RA inflammation, pain, angiogenesis, and cartilage destruction.